pentoxifylline has been researched along with Penile Induration in 17 studies
Penile Induration: A condition characterized by hardening of the PENIS due to the formation of fibrous plaques on the dorsolateral aspect of the PENIS, usually involving the membrane (tunica albuginea) surrounding the erectile tissue (corpus cavernosum penis). This may eventually cause a painful deformity of the shaft or constriction of the urethra, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our results support the hypothesis that the increase in NO and/or cGMP/cAMP levels by long-term administration of nitrergic agents or inhibitors of PDE, may be effective in reversing the fibrosis of PD, and more speculatively, other fibrotic conditions." | 5.32 | L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. ( Ferrini, MG; Gonzalez-Cadavid, NF; Qian, A; Rajfer, J; Valente, EG; Vernet, D, 2003) |
| "BACKGROUND Peyronie's disease is a chronic inflammatory disease involving the tunica albuginea of the penile corpora cavernosa." | 1.72 | Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases. ( De Giorgio, G; Paulis, G, 2022) |
| "Conservative medical approaches encompass oral, topical, and physical treatment." | 1.72 | Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series. ( De Giorgio, G; Paulis, G, 2022) |
| "Surgery remains the most effective treatment for Peyronie's disease and is considered the gold standard." | 1.46 | Peyronie's disease - Watch out for the bend. ( Chung, E; Katz, DJ; Love, C; Shoshany, O, 2017) |
| " Our results support the hypothesis that the increase in NO and/or cGMP/cAMP levels by long-term administration of nitrergic agents or inhibitors of PDE, may be effective in reversing the fibrosis of PD, and more speculatively, other fibrotic conditions." | 1.32 | L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. ( Ferrini, MG; Gonzalez-Cadavid, NF; Qian, A; Rajfer, J; Valente, EG; Vernet, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Paulis, G | 2 |
| De Giorgio, G | 2 |
| Topcuoglu, M | 1 |
| Çakan, M | 1 |
| Love, C | 1 |
| Katz, DJ | 1 |
| Chung, E | 1 |
| Shoshany, O | 1 |
| Gallo, L | 1 |
| Sarnacchiaro, P | 1 |
| Ciociola, F | 1 |
| Colpi, GM | 1 |
| Tan, RB | 1 |
| Sangkum, P | 1 |
| Mitchell, GC | 1 |
| Hellstrom, WJ | 1 |
| Alizadeh, M | 1 |
| Karimi, F | 1 |
| Fallah, MR | 1 |
| Safarinejad, MR | 1 |
| Asgari, MA | 1 |
| Hosseini, SY | 1 |
| Dadkhah, F | 1 |
| Shindel, AW | 3 |
| Lin, G | 2 |
| Ning, H | 2 |
| Banie, L | 2 |
| Huang, YC | 3 |
| Liu, G | 2 |
| Lin, CS | 2 |
| Lue, TF | 4 |
| Smith, JF | 1 |
| Clavijo, RI | 1 |
| Flechner, L | 1 |
| Breyer, BN | 1 |
| Eisenberg, ML | 1 |
| Larsen, SM | 1 |
| Levine, LA | 3 |
| Valente, EG | 1 |
| Vernet, D | 1 |
| Ferrini, MG | 1 |
| Qian, A | 1 |
| Rajfer, J | 1 |
| Gonzalez-Cadavid, NF | 1 |
| Brant, WO | 1 |
| Dean, RC | 1 |
| Taylor, FL | 1 |
3 reviews available for pentoxifylline and Penile Induration
| Article | Year |
|---|---|
Update on medical management of Peyronie's disease.
Topics: 4-Aminobenzoic Acid; Administration, Topical; Adrenal Cortex Hormones; Disease Management; High-Ener | 2014 |
Peyronie's disease: review of nonsurgical treatment options.
Topics: 4-Aminobenzoic Acid; Calcium Channel Blockers; Carnitine; Colchicine; Collagenases; Combined Modalit | 2011 |
Non-surgical therapy of Peyronie's disease.
Topics: Animals; Arginine; Carnitine; Collagenases; Combined Modality Therapy; Electric Stimulation Therapy; | 2008 |
4 trials available for pentoxifylline and Penile Induration
| Article | Year |
|---|---|
Effects of long term sildenafil on the acute phase of Peyronie's disease in a combination treatment.
Topics: Colchicine; Erectile Dysfunction; Humans; Male; Pain; Penile Induration; Penis; Pentoxifylline; Retr | 2022 |
Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline.
Topics: Adult; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Iran; Male; Middle Aged; Pain; | 2014 |
A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease.
Topics: Adult; Chronic Disease; Coitus; Delayed-Action Preparations; Double-Blind Method; Humans; Male; Midd | 2010 |
Pentoxifylline treatment and penile calcifications in men with Peyronie's disease.
Topics: Adult; Aged; Calcinosis; Cohort Studies; Humans; Male; Middle Aged; Penile Induration; Penis; Pentox | 2011 |
10 other studies available for pentoxifylline and Penile Induration
| Article | Year |
|---|---|
Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases.
Topics: Antioxidants; Combined Modality Therapy; Diclofenac; Humans; Male; Middle Aged; Pain; Penile Indurat | 2022 |
Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.
Topics: Adult; Antioxidants; Combined Modality Therapy; Diclofenac; Humans; Male; Middle Aged; Pain; Penile | 2022 |
Peyronie's disease - Watch out for the bend.
Topics: General Practitioners; Humans; Male; Penile Induration; Pentoxifylline; Phosphodiesterase 5 Inhibito | 2017 |
Ten-year experience with multimodal treatment for acute phase Peyronie's disease: A real life clinical report.
Topics: Acute Disease; Administration, Oral; Arginine; Clinical Protocols; Combined Modality Therapy; Drug A | 2019 |
Peyronie's disease: a "triple oxygenant therapy".
Topics: Arginine; Carbolines; Drug Therapy, Combination; Free Radical Scavengers; Humans; Male; Penile Indur | 2013 |
Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.
Topics: Cell Division; Collagen Type I; Elastic Tissue; Extracellular Matrix; Fibroblasts; Humans; In Vitro | 2010 |
Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1.
Topics: Blotting, Western; Carrier Proteins; Collagen; Dose-Response Relationship, Drug; Down-Regulation; El | 2010 |
Current approach to the man with acute phase Peyronie's disease--case presentation and discussion.
Topics: Adult; Arginine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; H | 2011 |
L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
Topics: Animals; Apoptosis; Arginine; Blotting, Western; Cyclic GMP; Enzyme Inhibitors; Fibrosis; Humans; Ma | 2003 |
Treatment of Peyronie's disease with oral pentoxifylline.
Topics: Administration, Oral; Humans; Male; Middle Aged; Penile Induration; Pentoxifylline; Ultrasonography; | 2006 |